Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free BXP Stock Alerts

Beximco Pharmaceuticals (BXP) Competitors

Beximco Pharmaceuticals logo
Compare

BXP vs. SIR, SAFE, CLIN, GROW, and SAGA

Should you buy Beximco Pharmaceuticals stock or one of its competitors? MarketBeat compares Beximco Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beximco Pharmaceuticals include Secure Income REIT (SIR), Safestore (SAFE), Clinigen Group (CLIN), Molten Ventures (GROW), and Saga (SAGA).

How does Beximco Pharmaceuticals compare to Secure Income REIT?

Beximco Pharmaceuticals (LON:BXP) and Secure Income REIT (LON:SIR) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Beximco Pharmaceuticals has a net margin of 16.76% compared to Secure Income REIT's net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 11.99% beat Secure Income REIT's return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Secure Income REIT N/A N/A N/A

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Secure Income REIT. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Secure Income REIT. Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Secure Income REIT'saverage media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Secure Income REIT Neutral

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Beximco Pharmaceuticals has higher revenue and earnings than Secure Income REIT.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A
Secure Income REIT£122.40M0.00N/A£0.62N/A

Summary

Beximco Pharmaceuticals beats Secure Income REIT on 8 of the 9 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Safestore?

Safestore (LON:SAFE) and Beximco Pharmaceuticals (LON:BXP) are related small-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Safestore has a beta of 1.149, meaning that its share price is 15% more volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.251, meaning that its share price is 75% less volatile than the broader market.

57.4% of Safestore shares are held by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 7.9% of Safestore shares are held by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Beximco Pharmaceuticals has higher revenue and earnings than Safestore. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Safestore, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Safestore£242.10M5.55£263.67M£29.7020.72
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A

Safestore presently has a consensus target price of GBX 734, suggesting a potential upside of 19.25%. Given Safestore's stronger consensus rating and higher probable upside, equities research analysts clearly believe Safestore is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Safestore
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Safestore has a net margin of 26.93% compared to Beximco Pharmaceuticals' net margin of 16.76%. Beximco Pharmaceuticals' return on equity of 11.99% beat Safestore's return on equity.

Company Net Margins Return on Equity Return on Assets
Safestore26.93% 2.86% 2.81%
Beximco Pharmaceuticals 16.76%11.99%6.97%

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Safestore. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Safestore. Safestore's average media sentiment score of 0.59 beat Beximco Pharmaceuticals' score of 0.00 indicating that Safestore is being referred to more favorably in the media.

Company Overall Sentiment
Safestore Positive
Beximco Pharmaceuticals Neutral

Summary

Safestore beats Beximco Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Clinigen Group?

Clinigen Group (LON:CLIN) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Beximco Pharmaceuticals has a net margin of 16.76% compared to Clinigen Group's net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 11.99% beat Clinigen Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Clinigen GroupN/A N/A N/A
Beximco Pharmaceuticals 16.76%11.99%6.97%

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Clinigen Group. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Clinigen Group. Clinigen Group's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Clinigen Group Neutral
Beximco Pharmaceuticals Neutral

Beximco Pharmaceuticals has higher revenue and earnings than Clinigen Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clinigen Group£565.60M0.00N/A£14.30N/A
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A

Summary

Beximco Pharmaceuticals beats Clinigen Group on 8 of the 9 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Molten Ventures?

Beximco Pharmaceuticals (LON:BXP) and Molten Ventures (LON:GROW) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Molten Ventures has a consensus price target of GBX 638.67, suggesting a potential upside of 5.22%. Given Molten Ventures' stronger consensus rating and higher possible upside, analysts clearly believe Molten Ventures is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Molten Ventures
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Beximco Pharmaceuticals has higher revenue and earnings than Molten Ventures. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Molten Ventures, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A
Molten Ventures£148M7.06-£33.58M£69.008.80

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. Comparatively, 41.0% of Molten Ventures shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Molten Ventures shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Molten Ventures had 3 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 4 mentions for Molten Ventures and 1 mentions for Beximco Pharmaceuticals. Molten Ventures' average media sentiment score of 0.00 beat Beximco Pharmaceuticals' score of 0.00 indicating that Molten Ventures is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beximco Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Molten Ventures
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Molten Ventures has a net margin of 75.09% compared to Beximco Pharmaceuticals' net margin of 16.76%. Beximco Pharmaceuticals' return on equity of 11.99% beat Molten Ventures' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Molten Ventures 75.09%9.21%-3.46%

Beximco Pharmaceuticals has a beta of 0.251, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Molten Ventures has a beta of 1.307, meaning that its stock price is 31% more volatile than the broader market.

Summary

Molten Ventures beats Beximco Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Saga?

Saga (LON:SAGA) and Beximco Pharmaceuticals (LON:BXP) are related small-cap companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Beximco Pharmaceuticals has higher revenue and earnings than Saga. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Saga, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Saga£660M1.49-£147.23M£2.40281.28
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A

Saga has a beta of 2.021, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.251, suggesting that its stock price is 75% less volatile than the broader market.

In the previous week, Saga had 6 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 7 mentions for Saga and 1 mentions for Beximco Pharmaceuticals. Saga's average media sentiment score of 0.28 beat Beximco Pharmaceuticals' score of 0.00 indicating that Saga is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Saga
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Beximco Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Beximco Pharmaceuticals has a net margin of 16.76% compared to Saga's net margin of -1.53%. Beximco Pharmaceuticals' return on equity of 11.99% beat Saga's return on equity.

Company Net Margins Return on Equity Return on Assets
Saga-1.53% -15.72% 2.90%
Beximco Pharmaceuticals 16.76%11.99%6.97%

Saga presently has a consensus target price of GBX 910, indicating a potential upside of 34.80%. Given Saga's stronger consensus rating and higher possible upside, research analysts clearly believe Saga is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Saga
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

13.5% of Saga shares are held by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 30.4% of Saga shares are held by insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Saga beats Beximco Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Beximco Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BXP vs. The Competition

Export
MetricBeximco PharmaceuticalsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£236.44M£12.89B£7.23B£2.61B
Dividend Yield5.67%2.72%2.59%6.16%
P/E Ratio0.03796.49281.76368.29
Price / SalesN/A938.32641.2784,160.88
Price / CashN/A76.5771.0227.89
Price / BookN/A10.9211.097.04
Net Income£970.84B£2.82B£3.50B£5.89B
7 Day PerformanceN/A-0.23%-0.28%6.44%
1 Month Performance3.97%-3.32%-3.01%0.09%
1 Year Performance35.90%155.28%61.94%63.74%

Beximco Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BXP
Beximco Pharmaceuticals
N/AN/AN/A+35.9%£236.44M£53.93B0.035,500
SIR
Secure Income REIT
N/AN/AN/AN/A£1.49B£122.40M743.55N/A
SAFE
Safestore
4.2723 of 5 stars		GBX 615.50
+0.5%		GBX 762.67
+23.9%		-8.6%£1.34B£242.10M20.72120
CLIN
Clinigen Group
N/AN/AN/AN/A£1.23B£565.60M64.691,000
GROW
Molten Ventures
1.5388 of 5 stars		GBX 622.50
+4.7%		GBX 638.67
+2.6%		+71.1%£1.07B£148M9.0220

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BXP) was last updated on 8/1/2026 by MarketBeat.com Staff.
From Our Partners
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel